Generation of an In Vitro Cell Culture Model of Malaria-HIV Co-Infection
JoVE Encyclopedia of Experiments
Immunology
0 views • 2:49 min • July 8th, 2025
Loading...
Overview
This study outlines a co-infection model using human peripheral blood mononuclear cells (PBMCs) to investigate the interactions between HIV and Plasmodium falciparum. The model demonstrates how HIV infection can disrupt immune responses to malaria, leading to persistent co-infection.
Key Study Components
Area of Science
- Immunology
- Infectious Diseases
- Cell Culture Techniques
Background
- HIV-infected CD4 T cells integrate proviral DNA.
- Plasmodium falciparum parasitized erythrocytes (PfRBCs) express specific antigens.
- Immune cell activation leads to cytokine release.
- Persistent malaria infection can occur due to HIV's impact on immune responses.
Purpose of Study
- To establish a co-infection cell culture model.
- To analyze the effects of HIV on immune responses to malaria.
- To understand the mechanisms of HIV and malaria co-infection.
Methods Used
- Isolation of PBMCs from HIV-positive and HIV-negative donors.
- Co-culture of PBMCs with PfRBCs and uninfected RBCs.
- Incubation to allow for immune cell activation and cytokine release.
- Collection and analysis of culture supernatant for viral and cytokine content.
Main Results
- HIV infection leads to altered cytokine secretion.
- Co-infection with PfRBCs exacerbates HIV replication.
- Malaria parasites proliferate in the presence of HIV-infected cells.
- The model provides insights into the dynamics of co-infection.
Conclusions
- The co-infection model is effective for studying HIV and malaria interactions.
- Understanding these interactions may inform treatment strategies.
- Further research is needed to explore therapeutic implications.
Frequently Asked Questions
What are PBMCs?
PBMCs are blood cells that play a crucial role in the immune response, including lymphocytes and monocytes.
How does HIV affect immune responses?
HIV can impair the function of immune cells, leading to reduced cytokine secretion and compromised immune responses.
What is the significance of PfRBCs in this study?
PfRBCs are used to study how malaria antigens interact with immune cells in the context of HIV infection.
What methods are used to analyze the culture supernatant?
The supernatant is analyzed for viral RNA and cytokine levels to assess the impact of co-infection.
Why is this co-infection model important?
It helps researchers understand the complex interactions between HIV and malaria, which can inform treatment approaches.
Executive Industry Relevance
This in vitro co-infection model enables mechanistic interrogation of HIV-malaria interactions, supporting target validation in infectious disease research. By quantifying cytokine release and viral replication dynamics, it provides predictive insights for de-risking dual-target therapeutic strategies. The model addresses a critical gap in preclinical evaluation of immunomodulatory interventions for co-endemic pathogens.
Strategic Applications in Biopharma R&D
Early Discovery & Target Validation
- Scientific Value: Interrogates therapeutic hypotheses regarding HIV-induced immune dysregulation in malaria co-infection.
- Operational Value: Enables functional validation of immunomodulatory targets using primary human immune cells.
- Predictive Value: Supports portfolio triage by quantifying cytokine thresholds linked to viral persistence.
Screening & Assay Development
- Scientific Value: Prepares standardized biological systems for compound screening against dual-pathogen modulation.
- Operational Value: Delivers reproducible cytokine and viral readouts for assay optimization.
- Scalability: Supports multi-well plate formats conducive to medium-throughput screening.
Translational & Preclinical Research
- Translational Value: Maintains disease relevance through primary human PBMCs and Plasmodium falciparum antigens.
- Mechanistic De-risking: Clarifies causal links between HIV-driven immune impairment and malaria parasite proliferation.
- Preclinical Continuity: Bridges discovery to in vivo models by defining immune correlates of co-infection severity.
Pipeline & Workflow Integration
The model integrates into early discovery workflows to inform target selection and mechanistic understanding before lead optimization.
- Discovery Biology: Tests hypotheses on cytokine-mediated viral reactivation and immune evasion pathways.
- Screening: Enables assessment of compound effects on HIV replication and malaria antigen-driven immune activation.
- Analytics: Provides quantitative viral RNA and cytokine measurements for comparative condition analysis.
- Translational Research: Connects immune profiling to preclinical validation of immunomodulatory candidates.
- Enterprise Reuse: Establishes a reusable platform for studying pathogen-immune interactions in co-infection contexts.
Operational & Enterprise Impact
- Scientific Value: Reduces mechanistic ambiguity in HIV-malaria pathogenesis through controlled co-culture.
- Operational Value: Ensures reproducibility via standardized PBMC seeding and parasite antigen exposure.
- Strategic Value: Improves go/no-go decisions by identifying targets that modulate dual-pathogen immune environments.
- Portfolio Impact: Enables risk-adjusted prioritization of immunomodulators based on co-infection biomarker modulation.
Implementation Considerations
- Requires expertise in primary immune cell culture and pathogen handling.
- Dependent on access to HIV-positive donor PBMCs and Plasmodium falciparum culture.
- Necessitates standardized cytokine and viral RNA assay platforms for cross-functional data alignment.
- Adaptation considerations include variability in donor immune status and parasite strain antigenicity.
- Practical limitations include donor-to-donor variability in HIV proviral load and parasite growth rates.
Biopharma FAQs
Why does cytokine measurement matter for target validation in HIV-malaria co-infection?
Cytokine levels indicate immune cell activation status and HIV transcriptional activity, providing a functional readout for target engagement. Measuring cytokine secretion enables assessment of how immunomodulatory compounds affect both pathogen environments. This supports target validation by linking mechanism to immune phenotype in co-infection models.
How does isolating HIV-infected PBMCs as an independent variable improve discovery pipeline fidelity?
Using HIV-infected PBMCs as a defined variable controls for proviral load and immune dysregulation, isolating HIV's specific contribution to malaria pathogenesis. This enables precise attribution of observed effects to HIV status rather than donor variability. It improves pipeline fidelity by reducing confounding in target mechanism studies.
What quantitative measurements of viral RNA and cytokines enable predictive confidence in co-infection models?
Quantitative PCR for HIV RNA and ELISA for cytokines (e.g., IL-6, TNF-α) provide measurable outputs to assess co-infection dynamics. These measurements allow comparison across experimental conditions and compound treatments. Thresholds for viral suppression or immune modulation can inform go/no-go decisions in preclinical development.
Why do replication requirements matter for cross-functional collaboration in co-infection model adoption?
Replication across wells and donors ensures data reliability, which is essential for aligning discovery, screening, and preclinical teams on target validity. Consistent results build confidence in the model’s ability to predict biological responses. This supports standardized use across departments for target validation and assay development.
What statistical analysis capabilities are required before implementing this co-infection model in screening workflows?
Capabilities to compare means across groups (e.g., t-tests, ANOVA) and assess correlation between cytokine levels and viral load are needed. These analyses determine whether observed differences are statistically significant and biologically relevant. Implementing appropriate statistics ensures robust interpretation of screening hits and target modulation effects.
08:11
Assessing the Innate Sensing of HIV-1 Infected CD4+ T Cells by Plasmacytoid Dendritic Cells Using an Ex vivo Co-culture System.
Related Videos
0 Views
07:36
Contact-Free Co-Culture Model for the Study of Innate Immune Cell Activation During Respiratory Virus Infection
Related Videos
0 Views
12:21
A Mouse Model for the Transition of Streptococcus pneumoniae from Colonizer to Pathogen upon Viral Co-Infection Recapitulates Age-Exacerbated Illness
Related Videos
0 Views
07:39
An In vitro Co-infection Model to Study Plasmodium falciparum-HIV-1 Interactions in Human Primary Monocyte-derived Immune Cells
Related Videos
0 Views
04:51
A Human Cervical Mucosa Infection Model to Study HIV Pathogenesis in Ex Vivo Conditions
Related Videos
0 Views
03:28
Generation of a Mouse Model of Experimental Cerebral Malaria Using Host Mosquito-Derived Sporozoites
Related Videos
0 Views
09:02
An Experimental Model to Study Tuberculosis-Malaria Coinfection upon Natural Transmission of Mycobacterium tuberculosis and Plasmodium berghei
Related Videos
0 Views
08:14
An In Vitro Model for Measuring Immune Responses to Malaria in the Context of HIV Co-infection
Related Videos
0 Views
11:38
Stem-cell Based Engineered Immunity Against HIV Infection in the Humanized Mouse Model
Related Videos
0 Views
09:23
Plasmodium falciparum Gametocyte Culture and Mosquito Infection Through Artificial Membrane Feeding
Related Videos
0 Views
Last updated: 18 July 2026